Valentina Fuoco

Valentina Fuoco

Auto-generated profile, based on publicly available information

Valentina Fuoco

Nuclear Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CRChiara Romanò
Chiara Romanò
SMStefania Mazzaglia
Stefania Mazzaglia
MMMarco Maccauro
Marco Maccauro
CSCarlo Spreafico
Carlo Spreafico
AGAlejandro Gabutti
Alejandro Gabutti
CCCarlo Chiesa
Carlo Chiesa
In this confirmatory study, we tested if a calculation that included the non-uniformity of dose deposition through a voxel-based dosimetric variable Ψ was able to improve the dose–response agreement with respect to the mean absorbed dose D. We performed dosimetry with 99mTc-MAA SPECT/CT and 90Y-PET/CT in 86 patients treated 8 instead of 4 days after the reference date with 2.8 times more 90Y glass microspheres/GBq than in our previous study. The lesion-by-lesion response was assessed with the mRECIST method and with an experimental densitometric criterion. A total of 106 lesions were studied. Considering Ψ as a prognostic response marker, having no Ψ provided a significantly higher AUC than D. The correlation, t-test, and AUC values were statistically significant only with the densitometric method and only with post-therapy dosimetry. In comparison with our previous study, the dose–response correlation and AUC values were poorer (maximum r = 0.43, R2 = 0.14, maximal AUC = 0.71), and the efficacy at a high dose did not reach 100%. The expected advantages of voxel dosimetry were nullified by the correlation between any Ψ and D due to the limited image spatial resolution. The lower AUC and efficacy may be explained by the mega-clustering effect triggered by the higher number of microspheres/GBq injected on day 8.

18 August 2021 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
VFValentina Fuoco
Valentina Fuoco
GAGiovanni Argiroffi
Giovanni Argiroffi
SMStefania Mazzaglia
Stefania Mazzaglia
ALAlice Lorenzoni
Alice Lorenzoni
VGValentina Guadalupi
Valentina Guadalupi
MMMarco Maccauro
Marco Maccauro
Objective: To give an updated overview on clinical aspects and survival effects of lutetium-177–prostate-specific membrane antigen (PSMA) (177Lu-PSMA) radioligand therapy (RLT), a novel treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: PubMed/MEDLINE database was searched for relevant articles published up to March 2021. The search was restricted to English-language articles. Results: Current evidence from the literature consistently demonstrated the efficacy, safety, and survival benefit of 177Lu-PSMA RLT in mCRPC. However, current data rely predominantly on retrospective analyses, showing heterogeneity of patient population and treatment protocols. More recently, results from the first randomized phase II study (TheraP) demonstrated that 177Lu-PMSA therapy significantly improved prostate-specific antigen response rate (66% vs 37%) and had fewer grade 3/4 adverse events when compared to cabazitaxel in patients with docetaxel-pretreated, progressive mCRPC. This review is intended to provide an updated overview of treatment protocols and responses, toxicity profile, and survival effects of 177Lu-PSMA RLT. Conclusions: 177Lu-PSMA RLT has emerged as a promising targeted treatment in mCRPC. It is currently applied in compassionate use programs and following exhaustion of approved therapies. Crucial for establishing this treatment in routine clinical management will be the results of the phase III VISION trial, which may confirm the encouraging patient outcomes reported to date.

27 May 2022 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
VFValentina Fuoco
Valentina Fuoco
MBMarta Barisella
Marta Barisella
ALAlice Lorenzoni
Alice Lorenzoni
EVElena Verzoni
Elena Verzoni
MMMarco Maccauro
Marco Maccauro
Somatostatin receptor scintigraphy with 99mTc-Tektrotyd is widely used for the investigation of neuroendocrine tumors. Overexpression of somatostatin receptors has been shown in different tumor types including lymphomas, breast carcinoma, and renal cell carcinoma (RCC). Isolated case reports have shown that RCC metastases can be identified using somatostatin receptor imaging such as Octreoscan scintigraphy and 68Ga-DOTATATE PET/CT. We report the case of a 70-year-old man with a history of surgically removed RCC who referred to 99mTc-Tektrotyd scintigraphy for the evaluation of a pancreatic tail lesion. The scan revealed intense tracer uptake in a left splenius cervicis muscle lesion that on biopsy was consistent with metastatic RCC.